The Market Aktie
WKN DE: A3E16Q / ISIN: AU0000306037
06.02.2025 23:00:31
|
Why AstraZeneca Topped the Market on Thursday
A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday. Investors were clearly impressed by the pharmaceutical company's numbers, as the stock closed the day more than 2% higher in value. This was notably better than the 0.4% bump of the S&P 500 index.AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 2023's figure. On the bottom line the company's "core" (i.e., non-GAAP) earnings per share rose even more sharply, advancing by 44% to $2.09. There was quite some distance between AstraZeneca's performance and analyst estimates for the quarter. On average, pundits following the company were anticipating it would post a lower revenue number ($14.15 billion) and a far lower adjusted net profit of $1.06 per share. Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLCmehr Nachrichten
15:59 |
Zuversicht in London: FTSE 100 steigt nachmittags (finanzen.at) | |
12:27 |
Freundlicher Handel: STOXX 50 am Mittag in Grün (finanzen.at) | |
12:27 |
Freundlicher Handel in London: FTSE 100 am Mittwochmittag im Plus (finanzen.at) | |
09:29 |
Freundlicher Handel in Europa: STOXX 50 präsentiert sich zum Handelsstart fester (finanzen.at) | |
09:29 |
Börse London in Grün: FTSE 100 zum Start mit positivem Vorzeichen (finanzen.at) | |
07.10.25 |
Börse London in Grün: FTSE 100 legt zum Ende des Dienstagshandels zu (finanzen.at) | |
07.10.25 |
Freundlicher Handel in London: FTSE 100 nachmittags mit Zuschlägen (finanzen.at) | |
07.10.25 |
Schwache Performance in London: FTSE 100 verbucht am Mittag Verluste (finanzen.at) |
Analysen zu AstraZeneca PLCmehr Analysen
07.10.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
07.10.25 | AstraZeneca Outperform | Bernstein Research | |
06.10.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
02.10.25 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
29.09.25 | AstraZeneca Overweight | JP Morgan Chase & Co. |
Aktien in diesem Artikel
AstraZeneca PLC ADR Cert. Deposito Arg. Repr. 2 ADRs | 67 025,00 | 3,39% |
|
AstraZeneca PLC | 147,80 | 0,75% |
|
AstraZeneca PLC (spons. ADRs) | 73,50 | 0,68% |
|